🔍 Hidden Gem Screener

Significant toll rate revision or a large new HAM/BOT project award win that materially improves revenue visibility and triggers consensus earnings upgrades — specifically, announcement of a project pipeline worth >₹5000 Cr in a single NHAI award cycle.

First quarter of positive EBITDA — demonstrating that fixed-cost leverage on manufacturing and S&M spend has crossed breakeven threshold, validating the operating leverage narrative concretely.

Full-year FY26 annual results confirming EBITDA margin sustained above 25% and positive PAT, alongside any announcement of asset monetisation or REIT-adjacent restructuring — converting the earnings inflection into a credible profit-growth story for institutional buyers.

Announcement of a new OEM export contract or PLI incentive disbursement confirmation that validates the China+1 positioning — or inclusion in a mid/smallcap index that forces passive fund buying given current zero institutional coverage.

Full-year FY26 results demonstrating sustained EBITDA margins above 60% alongside disclosed AUM growth in the wealth/PMS segment — concrete proof that margin expansion is structural (mix shift) rather than a cyclical trading-volume spike tied to the FY24-25 bull market.

Quarterly EBITDA margin expansion above 12% sustained for two consecutive quarters alongside same-store sales growth (SSSG) turning meaningfully positive, confirming that new store additions are maturing and fixed costs are genuinely being leveraged — not just topline growth masking margin dilution from immature stores.

Announcement of new project launches or booking milestones in FY27 pipeline that demonstrate revenue visibility beyond current completions, combined with a second consecutive year of D/E below 0.5x in FY26 annual results — signaling the deleveraging is structural, not cyclical.

Sustained margin improvement to 16%+ EBITDA in a reported quarter, combined with a large enterprise or carrier contract win announcement that demonstrates pricing power beyond bulk SMS arbitrage — ideally accompanied by reduction or elimination of promoter pledge.

Formal analyst initiations (3+ brokerages) post a strong Q2/Q3FY26 earnings print demonstrating EBITDA margin sustenance above 25% and order book visibility — institutional reclassification from 'small-cap industrial' to 'high-ROCE capital goods compounder' triggers multiple re-rating.

A large central or state government IT infrastructure contract win (₹200Cr+) disclosed via exchange filing, or inclusion in a smallcap index triggering passive and institutional flows — either would force analyst initiation and compress the PE from 13.5x toward sector peers at 20-25x.

Sustained EBITDA margin holding above 14% for two consecutive quarters combined with a formal order book disclosure or capacity utilisation update that confirms the margin expansion is structural rather than a one-time mix or pricing tailwind — forcing the market to re-rate from cyclical to quality compounder multiples.

Quarterly results showing PAT scaling proportionally with revenue (operating leverage inflection visible in EBITDA margin expansion), combined with any RERA-registered project launch in Mumbai's redevelopment pipeline that signals revenue visibility for FY27-28.

Commissioning of Waaree's 5.4 GW integrated manufacturing facility (cells + modules) in Gujarat, combined with a large US export order book crystallizing into revenue — this transforms the margin and capacity story from 'promise' to 'proof', forcing a re-rating of earnings multiples.

Initiation of analyst coverage by a mid-cap focused brokerage or inclusion in a smallcap index triggers institutional discovery; alternatively, a full-year FY26 earnings print that sustains >40% revenue growth with expanding margins forces a re-rating from 'cheap cyclical' to 'quality compounder' framing.

Quarterly EBITDA margin expansion crossing 18-20% threshold as fixed-cost base is fully absorbed by the doubled revenue base — this would be the concrete proof point that operating leverage is structural, not cyclical, triggering coverage initiation by larger brokerages.

A large OEM supply contract win or PLI incentive disbursement announcement tied to the auto components scheme — either would force institutional discovery and compress the valuation discount versus comparable debt-free auto ancillaries trading at 30-35x PE.

Formal PLI scheme disbursement or announcement of a large export order/capacity expansion that forces earnings estimate upgrades and puts the company on institutional radar screens for the first time.

Sustained revenue acceleration in the dental prosthetics/CAD-CAM segment driving EBITDA margins crossing 18-20%, combined with a formal PLI disbursement announcement or export order win that forces analyst upgrades and triggers institutional coverage initiation.

Announcement of a large PM-KUSUM Component-C state tender win (Maharashtra, Rajasthan, or UP) or Q1FY27 results showing EBITDA margin sustaining above 21% with revenue growth >25% YoY — either would force institutional analysts to initiate coverage and re-rate the stock from a cyclical pump company to a renewable energy infrastructure play.

Full-year FY26 results showing EBITDA margin expansion of 150-200bps YoY alongside a formal debt-free declaration (net D/E ~0x), which would force peer re-rating comparisons to Polycab/KEI at 30-40x PE vs current 16.8x.

Recognition of PLI Scheme benefits translating into export revenue growth — specifically new USFDA/EMA product approvals or PLI incentive disbursement announcements that demonstrate tangible top-line uplift beyond domestic API sales, forcing earnings estimate upgrades from the sparse 2-analyst coverage base.

Sustained EBITDA margin holding above 18% for two consecutive quarters combined with a large order win in export markets or domestic capex cycle for plastics/packaging, which would validate the margin expansion as structural rather than cyclical.

Securing a large PSU bank or payment aggregator contract that materially scales revenue beyond ₹250Cr run-rate, triggering first institutional analyst initiation and confirming the platform is not concentrated in a handful of clients

Sustained EBITDA margin above 33% for two consecutive quarters combined with a meaningful uptick in volumes from equity market retail participation cycle — this would make the operating leverage structural rather than cyclical, triggering potential institutional discovery at sub-10x PE.

Sustained revenue growth above ₹120Cr in FY26 annual results with EBITDA margin expansion confirming the operating leverage is structural rather than post-COVID mean reversion — triggering first institutional analyst coverage initiation.

Announcement of a large domestic pipeline order (₹500 Cr+) from GAIL, ONGC, or a CGD operator, or disclosure of export contract wins tied to Middle East/North Africa pipeline buildout — either would crystallize revenue visibility and force analyst coverage upgrades.

Formal institutional initiations (even 1-2 analyst reports) following a strong Q2FY27 earnings print showing credit costs stable below 1.5% alongside NIM expansion — this combination would simultaneously validate quality and trigger price discovery from ignored to discovered.

Formal analyst initiations (even 1-2 brokerages) combined with a demonstrable EBITDA margin improvement from current ~2-3% toward 3.5%+ in a quarterly result, signaling the business is moving up the value chain via PLI-linked distribution of locally manufactured IT hardware.

Sustained EBITDA margin expansion beyond 13-15% in upcoming quarterly results, combined with a meaningful order win announcement under PM Gati Shakti or related infrastructure programs that signals credible revenue visibility — triggering the first institutional analyst coverage initiation.

Announcement or confirmation of Specialty Steel PLI scheme disbursement/eligibility approval, combined with a sequential EBITDA margin expansion quarter (target >8-9% EBITDA margin vs current thin levels) that demonstrates fixed-cost leverage on the expanded revenue base — likely to appear in Q1/Q2FY27 results.

Announcement of a large wind EPC order win (₹300Cr+) or a multi-year O&M contract that materially extends revenue visibility beyond FY26, triggering the first institutional initiation report and forcing a sector PE re-rating from 11x toward the 18–22x peers command.

Sustained EBITDA margin expansion beyond 14% in a reported quarter — confirming the -3% to 12% trajectory is structural, not cyclical — would force initiation of analyst coverage and institutional attention. A geography expansion announcement (new state licensing) or a branded premium portfolio launch would be the concrete trigger.

Sustained revenue growth of 15%+ for two consecutive quarters driven by a structurally hotter summer cycle and premiumization of product mix (inverter/industrial coolers), which would justify current multiples and potentially trigger earnings estimate upgrades from the 7 covering analysts.

FY26 annual results (Q4FY26 earnings) confirming EBITDA margins holding above 28% alongside continued revenue growth — this would validate the operating leverage thesis and likely trigger initiations from mid-cap focused brokerages, compressing the discovery gap.

Sustained debt-free or near-zero-debt status confirmed in annual results combined with a second consecutive year of 28%+ EBITDA margins, which would trigger initial institutional screening and potential analyst initiation — driving a PE re-rating from ~13x toward sector peers at 20-25x.

Sustained EBITDA margin expansion beyond 14% for two consecutive quarters alongside meaningful free cash flow generation and debt reduction — proving the margin inflection is structural and not driven by temporary input cost tailwinds (ENA/glass prices).

Sustained EBITDA margin expansion above 10% for two consecutive quarters, or a disclosed order win linked to the Specialty Steel PLI scheme that provides revenue visibility — either would force discovery by small-cap funds screening on earnings momentum.

Capacity expansion commissioning (likely ECH/chlor-alkali downstream) driving next leg of revenue growth with margin expansion, combined with a second analyst initiating coverage — breaking the institutional invisibility barrier and forcing PE re-rating from 11x toward sector peers at 18-22x.

Announcement of a large multi-year government contract (₹100Cr+) in geospatial/digital infrastructure — specifically SVAMITVA Phase 2 expansion or a defence/urban mapping mandate — that validates revenue visibility and triggers institutional discovery given the PE-valuation disconnect.

Q2FY27 full-year results showing sustained NIM expansion alongside stable/improving GNPA below 3%, combined with a tier-1 institutional investor initiating coverage or a QIP at premium to current book — any of these would force a re-rating from distressed-lender discount to growth-NBFC multiple.

A Q2/Q3 quarterly result showing EBITDA margins sustaining above 8-9% alongside continued double-digit same-store-sales growth — confirming that the ROCE improvement is structural and not driven by the post-COVID jewellery demand surge alone.

Commercial scale-up and revenue recognition from the Li-ion battery anode material (natural/synthetic graphite) facility — securing a marquee EV OEM or cell manufacturer as anchor customer would force a fundamental re-classification from 'speciality chemical' to 'EV materials' and compress the discount to global anode material peers.

Formal announcement of PLI incentive receipt or approved beneficiary status in either the Pharma/API or Auto Components scheme, accompanied by a Q2/Q3FY27 result showing EBITDA margins holding above 12% on continued revenue growth — forcing analysts to initiate coverage and reclassify the stock from 'unrated micro-cap' to 'quality compounder'.

Recognition of PLI Specialty Steel benefits flowing into EBITDA margins (currently suppressed), combined with a potential order win announcement in steel pipes tied to infrastructure capex cycle — driving EBITDA margin expansion of 150-200bps that forces analyst coverage upgrades and PE re-rating toward 18-20x.

Sustained EBITDA margin holding above 12-15% for two consecutive quarters combined with net debt falling below ₹1500 Cr, which would force credit rating upgrades and bring institutional analysts back to coverage — directly compressing the distressed-company valuation discount currently embedded in a 0.46x P/B despite improving profitability.

First institutional analyst initiating coverage OR a PLI incentive disbursement/product approval that forces the market to reprice the quality of earnings — specifically, a disclosed PLI tranche receipt or a large supply contract win in API/pharma that validates the margin sustainability above 25% EBITDA.

Announcement of a meaningful EV OEM supply contract (e.g., Tata Motors, M&M, or a two-wheeler EV player) under PLI-linked capacity, or a Q2FY27 earnings print showing EBITDA margin expansion above 10% on operating leverage — whichever comes first would force analyst coverage upgrades and a re-rating of the multiple.